BRI projects face a multiplicity of issues from procurement to implementation. Investors must thoroughly understand and mitigate risks associated with BRI ventures.
The U.S. adds 12 Chinese entities to its export blacklist; Rules regulating listed companies to be consolidated; Didi ordered by regulators to delist from NYSE
New rules are set forth for foreign-related certification. More details are required for working papers of securities offering sponsorship. Domestic bond credit rating is relied on more for insurance capital investment.
Hong Kong finalizes secondary listing reforms to attract more Greater China Issuers; SAMR fines tech giants for failing to declare transactions; and German insurer Allianz approved to take full control of life insurance business
In China's first-ever securities class action, Kangmei Pharmaceuticals has been ordered to pay $385 million as compensation—just enough for 50,000 investors to recoup their losses.
Data processors may not take biometric features as the sole method of authenticating individuals' identities. Anti-monopoly guidelines are set forth regarding the active pharmaceutical ingredient sector. Insurance capital may invest in REITs.
Hong Kong IPOs also subject to cybersecurity review; social, sustainability bond issuance pilot for foreign issuers; and U.S. law bars new equipment licenses for Chinese telecoms firms
Apps are required to inform users of third party use of their personal information. CSRC issues registration rules for public offerings of shares on the Beijing Stock Exchange. Beijing Municipality issues rules to prohibit misappropriation of housing purchase funds.
Guidelines are issued to classify internet platform operators and their responsibilities. Carbon trading derivatives are not mentioned in the latest law draft on futures and derivatives.
Hong Kong Court grants landmark interlocutory injunctions in IP Case; Draft amendment to Anti-Monopoly Law targets platform economy; 4 G-SIBs to comply with new TLAC requirements By 2025
